AKTX:NSD-Akari Therapeutics, Plc (USD)

COMMON STOCK | Biotechnology | NSD

Last Closing Price

USD 1.69

Change

+0.03 (+1.81)%

Market Cap

USD 0.07B

Volume

0.20M

Avg Analyst Target

N/A

Avg User Target

USD
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Akari Therapeutics, Plc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of treatments for autoinflammatory diseases that involve complement and leukotriene pathways. Its lead product candidate is nomacopan, a second-generation complement inhibitor that is in Phase II clinical trial for the treatment of autoimmune and inflammatory diseases, including paroxysmal nocturnal hemoglobinuria, guillain barré syndrome, hematopoietic stem cell transplant-associated thrombotic microangiopathy, and bullous pemphigoid. Akari Therapeutics, Plc is based in London, the United Kingdom.

Company Website : http://www.akaritx.com

Address : 75/76 Wimpole Street, London, United Kingdom, W1G 9RT

Employees : 9

Fiscal Year End : December

Currency: USD

Country : USA

Technical Indicators

Beta : 1.15

52 Week High : 4.21

Short Ratio : 0.20

52 Week Low : 1.42

Shorted Shares : 54,855

200 Day Moving Average : 2.33

Shorted Shares Previous Month : 97,330

50 Day Moving Average : 1.72

Shares Held By Insiders : 27.77%

Shares Held by Institutions : 19.23%

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-07-22 )

Largest Industry Peers for Biotechnology

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
MRNA Moderna, Inc

+2.37 (+0.74%)

 USD128.93B 215.22 167.82
BNTX BioNTech SE

+21.37 (+8.23%)

 USD62.70B 47.24 36.74
REGN Regeneron Pharmaceuticals, Inc

+3.16 (+0.54%)

 USD62.19B 16.62 13.12
VRTX Vertex Pharmaceuticals Incorpo..

-0.25 (-0.13%)

 USD50.81B 18.71 13.00
ALXN Alexion Pharmaceuticals, Inc

N/A

 USD40.34B 59.23 41.97
BGNE BeiGene, Ltd

+15.11 (+4.93%)

 USD29.15B N/A N/A
GMAB Genmab A/S

+0.21 (+0.48%)

 USD28.86B 32.84 3.64
SGEN Seagen Inc

-0.27 (-0.19%)

 USD26.06B 40.07 36.19
RPRX Royalty Pharma plc

-0.95 (-2.30%)

 USD25.34B 34.40 14.43
ALNY Alnylam Pharmaceuticals, Inc

+1.72 (+0.96%)

 USD21.17B N/A N/A

ETFs Containing AKTX

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Biotechnology)		 Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -8.65% 55% F 24% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -8.65% 55% F 24% F
Trailing 12 Months  
Capital Gain -15.50% 44% F 15% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.50% 44% F 15% F
Trailing 5 Years  
Capital Gain -80.77% 21% F 6% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -80.77% 21% F 5% F
Average Annual (5 Year Horizon)  
Capital Gain -17.09% 14% F 5% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -17.09% 13% F 5% F
Risk Return Profile  
Volatility (Standard Deviation) 45.03% 70% C- 40% F
Risk Adjusted Return -37.95% 15% F 7% F
Market Capitalization 0.07B 11% F 13% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Biotechnology)		 Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.00 44% F 73% C
Price/Book Ratio 16.52 10% F 8% F
Price / Cash Flow Ratio -3.88 29% F 62% D-
EV/EBITDA N/A N/A N/A N/A N/A
Management Effectiveness  
Return on Equity -666.66% 4% F 11% F
Return on Invested Capital -472.45% 1% F 1% F
Return on Assets -124.26% 2% F 1% F
Debt to Equity Ratio N/A N/A N/A N/A N/A
Technical Ratios  
Short Ratio 0.20 95% A 92% A-
Short Percent 0.27% 98% A+ 90% A-
Beta 1.15 62% D- 49% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

No discussions yet

User / Independent Analyst Ratings

User Name Target Rating Target Horizon (Months) Target Price User Analysis Date Comment

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to earnings

The stock is trading high compared to its peers on a price to earning basis and is above the sector median.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.